| News

T3 Pharma raises more than 12 million Swiss francs

26.09.2019

T3 Pharma, a Basel-based biotech company, has closed its second financing round and raised in excess of 12 million Swiss francs in the process. The company’s management has now also been strengthened as it seeks to bring its immuno-oncological product candidates into the clinical development phase.

Research (Img: Alex011973/shutterstock)

T3 Pharma, a spin-off affiliated with the University of Basel, develops immuno-oncological treatment methods to combat tumors. The company, which is supported by BaseLaunch, the healthcare accelerator of BaselArea.swiss, is now intending to enter the clinical development phase. In advance of this, it has now closed a second round of financing, as outlined in a press release. Doing so, T3 Pharma raised more than 12 million francs.

Both existing investors and two new investors in the form of Boehringer Ingelheim Venture Fund (BIFV) and Reference Capital SA took part in the financing round. Simon Ittig, CEO of T3 Pharma, was quoted in the press release: “The support of these investors validates our work and indicates that we are on the right track​”.

With the support of its investors and the Biocenter at the University of Basel, the leading product candidates of the Basel-based company are now set to be further developed. The focus is on a bacteria to be inserted into a tumor in order to produce therapeutic proteins within. Claire Barton, recently named Chief Medical Officer of T3 Pharma, will also be involved in this further development in the future. Barton has already worked with the company as a consultant over the past 18 months. Moreover, Frank Kalkbrenner, Managing Director of BIFV, has also been newly elected onto the Supervisory Board at T3 Pharma.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area – exactly the right chemistry for South Korean pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area – exactly the right chemistry for South Korean pharma companies

KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European market

Read More
Basel Area supporting three digital health startups
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area supporting three digital health startups

Basel Area Business & Innovation will be offering intensive support to the three winners of its DayOne Digital Health Accelerator...

Read More
Gray establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest

Gray establishes presence in Basel

The North American fully integrated specialty service provider Gray has established a subsidiary in Basel. The key factors in favor...

Read More
Artificial Intelligence able to identify potentially life-saving antibiotics
Basel Area Business & Innovation, Innovation, Invest

Artificial Intelligence able to identify potentially life-saving antibiotics

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...

Read More
Investors give Anaveon 110 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Investors give Anaveon 110 million Swiss francs

Anaveon has received investment commitments amounting to 110 million Swiss francs in a Serie B funding round. The Basel-based biopharmaceutical...

Read More
Basel alliance seeks to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest

Basel alliance seeks to combat antibiotic resistance

The Spearhead alliance has been founded in Basel with the aim of combating the silent pandemic of antimicrobial resistance. By...

Read More
Kinarus and Noorik awarded federal grants
Basel Area Business & Innovation, Innovation, Invest

Kinarus and Noorik awarded federal grants

The Basel-based biopharmaceutical companies Kinarus and Noorik have been awarded federal grants for their clinical trials investigating drug candidates to...

Read More
Alloy acquires deepCDR and will expand Basel site
Basel Area Business & Innovation, Innovation, Invest

Alloy acquires deepCDR and will expand Basel site

Alloy Therapeutics, a biotechnology firm from Boston in the USA, has acquired the Basel-based startup deepCDR Biologics. Alloy labs and...

Read More
Basel Healthtech fund successfully closed
Basel Area Business & Innovation, Innovation, Invest

Basel Healthtech fund successfully closed

The venture capital firm MTIP has announced the successful closing of its FUND II. It is one of the first...

Read More
Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.